For the Inventor, By the Inventor

Enter assignee name

San Carlos, CA, United States of America

Incelldx, Inc.

USPTO Granted Patents = 17

EPO Patents = 3

Trademarks = 5

Forward Citations = 22

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

Bruce K Patterson (15 out of 26 patents)

Amanda Noel Chargin (6 out of 6 patents)

Edgar B Francisco (5 out of 5 patents)

4. Amruta Pise (5 out of 5 patents)

5. Keith Shults (5 out of 8 patents)

6. Hallison Rodrigues (3 out of 3 patents)

7. Emily Long (2 out of 2 patents)

8. Seyedhamed Jafarianmohamady (2 out of 2 patents)

9. Fangfang Yin (1 out of 1 patent)

10. Min Song (1 out of 1 patent)

11. Srividyabhuvaneswari Subramaniam (1 out of 1 patent)

12. Grace Elaine Knutson (1 out of 1 patent)

17 patents: Sort by Forward Citations

1. 12516390 - Methods and Systems for Predicting Whether a Subject Has a Cervical Intraepithelial Neoplasia (CIN) Lesion from a Suspension Sample of Cervical Cells (2026-01-06),

2. 12298309 - Methods of assaying neoplastic and neoplasia-related cells and uses thereof (2025-05-13),

3. 12228580 - Methods of assigning a COVID pathological type based on a cytokine/chemokine panel (2025-02-18),

4. 11988658 - Methods of assessing cellular breast samples and compositions for use in practicing the same (2024-05-21),

5. 11952373 - Method of treating hypercytokinemia by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc (2024-04-09),

6. 11726089 - Methods of assaying neoplastic and neoplasia-related cells and uses thereof (2023-08-15),

7. 11629196 - Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions (2023-04-18),

8. 11402391 - Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist (2022-08-02),

9. 11180491 - Method of treating COVID-19 by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc (2021-11-23),

10. 10782298 - Methods of detecting per cell PD-L1 expression and uses thereof (2020-09-22),

11. 10627389 - Methods of assessing cellular breast samples and compositions for use in practicing the same (2020-04-21),

12. 10308990 - Methods of evaluating a cellular sample for latent cellular replication competent HIV-1 (2019-06-04),

13. 10167526 - Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion from a suspension sample of cervical cells (2019-01-01),

14. 10011884 - Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion from a suspension sample of cervical cells (2018-07-03),

15. 9464332 - HPV E6, E7 MRNA assay and methods of use thereof (2016-10-11),

Company Overview

Incelldx, Inc. is a biotechnology company based in San Carlos, California, specializing in the development of innovative diagnostic solutions for cancer and other diseases. The company focuses on leveraging advanced technologies, including molecular diagnostics and immunology, to enhance patient care and treatment outcomes. Incelldx aims to provide healthcare professionals with tools that facilitate early detection and personalized therapy, thereby improving the overall management of complex medical conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

17 Patents

#23 in San Carlos, CA

#4,518 in California

#18,903 in US

#35,948 in the World

San Carlos, CA, United States of America

Incelldx, Inc.

Forward Citations = 22

12 inventors:

Bruce K Patterson (15 out of 26 patents)

Amanda Noel Chargin (6 out of 6 patents)

Edgar B Francisco (5 out of 5 patents)

4. Amruta Pise (5 out of 5 patents)

5. Keith Shults (5 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Incelldx, Inc.. Retrieved from https://idiyas.com/company/incelldx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…